Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level
A Mega-analysis of Individual Participant-Level Data

Kate Merritt, PhD; Philip K. McGuire, FMedSci; Alice Egerton, PhD; and the 1H-MRS in Schizophrenia Investigators

**IMPORTANCE** Proton magnetic resonance spectroscopy (1H-MRS) studies indicate that altered brain glutamatergic function may be associated with the pathophysiology of schizophrenia and the response to antipsychotic treatment. However, the association of altered glutamatergic function with clinical and demographic factors is unclear.

**OBJECTIVE** To assess the associations of age, symptom severity, level of functioning, and antipsychotic treatment with brain glutamatergic metabolites.

**DATA SOURCES** The MEDLINE database was searched to identify journal articles published between January 1, 1980, and June 3, 2020, using the following search terms: MRS or magnetic resonance spectroscopy and (1) schizophrenia or (2) psychosis or (3) UHR or (4) ARMS or (5) ultra-high risk or (6) clinical high risk or (7) genetic high risk or (8) prodrome* or (9) schizoaffective. Authors of 1141 1H-MRS studies measuring glutamate (Glu) levels in patients with schizophrenia were contacted between January 2014 and June 2020 and asked to provide individual participant data.

**STUDY SELECTION** In total, 45 1H-MRS studies contributed data.

**DATA EXTRACTION AND SYNTHESIS** Associations of Glu, Glu plus glutamine (Glx), or total creatine plus phosphocreatine levels with age, antipsychotic medication dose, symptom severity, and functioning were assessed using linear mixed models, with study as a random factor.

**MAIN OUTCOMES AND MEASURES** Glu, Glx, and Cr values in the medial frontal cortex (MFC) and medial temporal lobe (MTL).

**RESULTS** In total, 42 studies were included, with data for 1251 patients with schizophrenia (mean [SD] age, 30.3 [10.4] years) and 1197 healthy volunteers (mean [SD] age, 27.5 [8.8] years). The MFC Glu ($F_{1,1211.9} = 4.311$, $P = .04$) and Glx ($F_{1,1079.2} = 5.287$, $P = .02$) levels were lower in patients than in healthy volunteers, and although creatine levels appeared lower in patients, the difference was not significant ($F_{1,1395.9} = 3.622$, $P = .06$). In both patients and volunteers, the MFC Glu level was negatively associated with age (Glu to Cr ratio, $F_{1,1352.4} = 47.533$, $P < .001$; cerebrospinal fluid–corrected Glu, $F_{1,1216.7} = 5.610$, $P = .02$), showing a 0.2-unit reduction per decade. In patients, antipsychotic dose (in chlorpromazine equivalents) was negatively associated with MFC Glu (estimate, 0.10 reduction per 100 mg; SE, 0.04) and MFC Glx (estimate, −0.01; SE, 0.04) levels. The MFC Glu to Cr ratio was positively associated with total symptom severity (estimate, 0.01 per 10 points; SE, 0.005) and positive symptom severity (estimate, 0.02; SE, 0.02) and was negatively associated with level of global functioning (estimate, 0.04; SE, 0.01). In the MTL, the Glx to Cr ratio was positively associated with total symptom severity (estimate, 0.06; SE, 0.03), negative symptoms (estimate, 0.2; SE, 0.07), and worse Clinical Global Impression score (estimate, 0.2 per point; SE, 0.06). The MFC creatine level increased with age (estimate, 0.2; SE, 0.05) but was not associated with either symptom severity or antipsychotic medication dose.

**CONCLUSIONS AND RELEVANCE** Findings from this mega-analysis suggest that lower brain Glu levels in patients with schizophrenia may be associated with antipsychotic medication exposure rather than with greater age-related decline. Higher brain Glu levels may act as a biomarker of illness severity in schizophrenia.

Published online April 21, 2021.

**Author Affiliations:** Division of Psychiatry, Institute of Mental Health, UCL, London, United Kingdom (Merritt); Psychosis Studies Department, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, United Kingdom (Merritt, McGuire, Egerton).

**Group Information:** The 1H-MRS in Schizophrenia Investigators authors and nonauthor collaborators appear at the end of the article.

**Corresponding Author:** Kate Merritt, PhD, Division of Psychiatry, Institute of Mental Health, UCL, Sixth Floor, Maple House, London W1T 7BN, United Kingdom (k.merritt@ucl.ac.uk).
Glutamatergic dysfunction is implicated in the pathophysiology of schizophrenia, but the nature of this dysfunction may change over the course of illness. Aspects of glutamatergic dysfunction can be investigated in vivo using proton magnetic resonance spectroscopy (1H-MRS), which measures the total amount of intracellular and extracellular glutamate (Glu) in a predefined voxel of interest. Meta-analyses of 1H-MRS studies indicate that glutamatergic metabolites are elevated in patients with schizophrenia compared with healthy volunteers; however, a recent meta-analysis of 7-T MRS studies reports lower Glu levels in patients, and individual studies show variable results. This heterogeneity may be associated with factors such as age, illness duration, symptom severity, illicit substance use, and antipsychotic medication exposure, which vary between cohorts. The associations of such factors are best examined in large data sets incorporating patients across different stages of illness.

There is some indication that elevations in 1H-MRS glutamatergic metabolite levels may be most apparent in early psychosis but reduced in chronic schizophrenia. This finding may be associated with the expression of dysfunctional compensatory processes that emerge secondary to the illness but may also be associated with other factors (eg, divergence from normal aging processes or medication exposure lasting many years). Large studies have not yet reached a consensus on the associations of aging with Glu levels in patients with schizophrenia. An age-related decrease in medial frontal cortex (MFC) Glu level has been observed in both patients and healthy volunteers, but these findings were not replicated by another large study. Alternatively, metaregression analysis has detected accelerated MFC glutamatergic reductions in patients with schizophrenia compared with healthy volunteers, but this finding was not apparent in a more recent analysis. Metaregression analyses are limited to using group mean data extracted from individual studies, and thus it is difficult to disentangle age-dependent associations from other clinical factors that correlate with age, such as the duration of illness or the duration of antipsychotic treatment. Indeed, a number of longitudinal studies have reported reductions in brain glutamatergic metabolite levels following antipsychotic treatment in the frontal and temporal lobes among other regions.

There is also a lack of consensus about whether brain glutamatergic metabolite levels are associated with symptom severity and global functioning. A systematic review found inconsistent evidence to correlate Glu levels to symptom severity, although many studies were limited by small sample sizes of patients with similar symptom profiles. Individual studies comparing symptomatic and nonsymptomatic patients have reported higher Glu plus glutamine (Glx) levels in the symptomatic group and elevated Glu levels in nonremitted patients compared with remitted patients. However, age may confound these associations if patients with more severe symptoms are younger.

With the aim of better characterizing glutamatergic dysfunction in schizophrenia, we conducted a mega-analysis of individual participant-level data examining the associations of age, antipsychotic medication exposure, diagnosis, symptom severity, and functioning with 1H-MRS measures of glutamatergic metabolite levels. We hypothesized that (1) glutamatergic metabolite levels would decrease in association with age in both healthy volunteers and patients; (2) glutamatergic metabolite levels would be associated with a decrease in the context of higher antipsychotic medication doses; (3) glutamatergic metabolite levels would be lower in patients than in healthy volunteers; and (4) more severe symptoms and worse global functioning would be associated with higher Glu levels. In addition, we tested the assumption that these factors are not associated with the combined creatine and phosphocreatine signal (Cr) because Glu is commonly reported in ratio to Cr for analyses.

**Methods**

The MEDLINE database was searched to identify journal articles published between January 1, 1980, and June 3, 2020, using the following search terms: MRS or magnetic resonance spectroscopy and (1) schizophrenia or (2) psychosis or (3) UHR or (4) ARMS or (5) ultra-high risk or (6) clinical high risk or (7) genetic high risk or (8) prodrome* or (9) schizoaffective. Authors of 1H-MRS studies were contacted at least twice between January 2014 and June 2020 to request anonymized participant-level 1H-MRS metabolite data, which included levels of Glu, glutamine, Glx, and Cr and Cramér-Rao Lower Bound values, which estimate metabolite goodness of fit. Clinical and demographic data included positive, negative, general, and total subscores of the Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF) scores, Clinical Global Impression (CGI) scores, age, duration of illness, antipsychotic medication dose, and duration of treatment. All methods and results are reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.

Analyses were restricted to variables for which a minimum of 3 independent data sets were available. Brain metabolite data were categorized into (1) the MFC, including the...
antior cingulate cortex and (2) medial temporal lobe (MTL), including the hippocampus. Data with Cramér-Rao Lower Bound values higher than 20% were excluded. Glutamate values are often corrected for the amount of cerebrospinal fluid (CSF) in the voxel because CSF contains negligible metabolites of interest. Alternatively, Glu is estimated relative to Cr. Herein, CSF-corrected and Cr-scaled values were aggregated separately.

Associations of Glu, Glx, or creatine levels with variables of interest were assessed using linear mixed models in R, version 3.6 (R Core Team),29 with the lmer and ggplot2 packages.30 Independent variables were entered as fixed factors, and study was entered as a random factor. Glutamate and Glx measures are not independent and thus were not corrected for multiple comparisons. Tests of collinearity determined which variables to include in the model. For analyses investigating the association of age with metabolites, model 1 investigated the direct association of age plus group (patient vs healthy volunteers), and model 2 assessed their interaction. The linear mixed models were estimated with maximum likelihoods because residual likelihoods are not comparable across models with different fixed effects.31 The lowest Akaike information criterion value indicates the best model,28 and χ² tests were used to assess which model was superior. To determine whether metabolite values in patients were best estimated by age or with chlorpromazine equivalent (CPZE) dose (when both were significantly associated with metabolite levels), model 1 included CPZE dose, and model 2 included both age and CPZE dose.

For symptom severity, we reduced the number of comparisons by first testing the association between metabolite levels and PANSS total score. When the association was significant, follow-up analyses investigated the PANSS positive and negative score in one model with restricted maximum likelihoods.29 To investigate the association between Glu level and functioning, GAF scores were examined. If GAF scores were unavailable, then CGI scores were examined. To determine whether patient metabolite values were best estimated by age or by PANSS total scores, model 1 included PANSS total scores, and model 2 included both age and PANSS total scores. For all comparisons, a 2-sided P < .05 was considered statistically significant.

Results

The literature search identified 114 studies (eFigure in the Supplement). Of those studies, 45 contributed data (eTable 1 in the Supplement). Two of these studies were not included because data were only available for ultra-high-risk participants,32,33 and 1 study was excluded because IH-MRS was conducted using a J-resolved acquisition approach.34 A total sample size of 1251 patients with schizophrenia (mean [SD] age, 30.3 [10.4] years) and 1197 healthy volunteers (mean [SD] age, 27.5 [8.8] years) were included in the analyses. Sample sizes from each study ranged from 10 to 89 healthy volunteers and from 10 to 147 patients. Twenty-four studies examined patients with first-episode psychosis,5,7,11,24,35-53 and 20 studies examined patients with established schizophrenia.11,14,25,35-36,38-40,44,54-63 Four studies did not include healthy volunteer data.24,32,61,64

Association of Demographic and Clinical Factors With Cr Level

In the MFC, Cr levels increased with age (F₁,1399.1 = 20.678, P < .001; n = 1417) (Figure 1) at a rate of 0.2 units per decade (SE = 0.05). This association did not differ between patients and healthy volunteers (Table 1). In the MTL, there was no association between Cr level and age. There were no significant associations of Cr level with CPZE dose, PANSS total symptoms, or GAF score in either the MFC or MTL.

Association of Age and CPZE Dose With Glutamatergic Metabolite Levels

Duration of illness was associated with age and therefore was not included in the model. Age was not significantly associated with CPZE dose (eTable 2 in the Supplement).

Across all participants, MFC Glu levels decreased with age (Glu to Cr ratio: F₁,1522.4 = 15.685, P < .001; n = 1534; CSF-corrected Glu level: F₁,1399.1 = 20.678, P < .001; n = 1417) (Figure 1). The Glu to Cr ratio decreased by 0.04 units per decade (SE = 0.006), and CSF-corrected Glu levels decreased by 0.2 units per decade (P = .07). There was no interaction between age and group (Table 1). The MFC Glx to Cr ratio also decreased with age (F₁,1345.4 = 15.685, P < .001; n = 1357), by 0.04 units per decade (SE = 0.01). The MFC CSF-corrected Glx level was not significantly associated with age.

Both the MFC CSF-corrected Glu and CSF-corrected Glx levels were negatively associated with CPZE dose (CSF-corrected Glu level: F₁,269.3 = 7.583, P = .006; n = 276; CSF-corrected Glx level: F₁,251.3 = 6.326, P = .01, n = 259) (Figure 2). The CSF-corrected Glu level decreased by 0.10 per 100 mg of the CPZE dose (SE = 0.03), and the CSF-corrected Glx level decreased by 0.11 per 100 mg of the CPZE dose (SE = 0.04). The associations of the CPZE dose with the Glu to Cr and Glx to Cr ratios were nonsignificant.

When assessing the association of age with CPZE dose in the same model, the model combining age and CPZE dose best estimated the MFC CSF-corrected Glu level (Table 1). In contrast to the MFC, in the MTL, the Glx to Cr ratio was not significantly associated with age (n = 143 patients with schizophrenia, n = 151 healthy volunteers) or with CPZE dose (n = 94). There were insufficient data to examine the Glu to Cr ratio, the CSF-corrected Glu level, or the CSF-corrected Glx level in the MTL.

Associations With Group

Both MFC CSF-corrected Glu and CSF-corrected Glx levels were lower in the schizophrenia group compared with the healthy volunteer group while controlling for age (F₁,1221.9 = 4.311, P = .04, n = 396 healthy volunteers, n = 630 patients with schizophrenia; F₁,1079.2 = 5.287, P = .02, n = 519 healthy volunteers, n = 573 patients with schizophrenia) (Table 1). There was no association of group with MFC Glu to Cr ratio or Glx to Cr ratio. However, although not statistically significant, MFC Cr levels were lower in patients compared with healthy vol-
unters while controlling for age ($F_{1,1395.9} = 3.622, \ P = .06, \ n = 712$ healthy volunteers, $n = 705$ patients with schizophrenia). In the MTL, the Cr level and the Glx to Cr ratio did not differ between patients and healthy volunteers.

**Association Between Glutamatergic Metabolite Levels and Symptom Severity**

The PANSS total, positive, general, and negative subscores were all intercorrelated (eTable 2 in the Supplement); therefore, the initial model examined the PANSS total score. When significant, follow-up analyses investigated the PANSS positive score and the PANSS negative score in 1 model.

The MFC Glu to Cr ratio was positively associated with the PANSS total score ($F_{1,659.1} = 5.819, \ P = .02, \ n = 668$) (Figure 3). The Glu to Cr ratio increased by 0.01 per 10 points on the PANSS scale ($SE = 0.005$). Subsequent analysis found a positive association between the Glu to Cr ratio and the PANSS positive score ($F_{1,635.7} = 4.382, \ P = .004, \ n = 625$), whereby the Glu to Cr ratio increased by 0.04 per 10 points ($SE = 0.02$). The PANSS negative score was nonsignificant. The MFC Glu to Cr ratio was negatively associated with the GAF score ($F_{1,171.8} = 13.152, \ P < .001, \ n = 178$) (Figure 3), such that the Glu to Cr ratio increased by 0.04 per 10-point reduction on the GAF scale ($SE = 0.01$). There were no associations of CSF-corrected Glu or Glx level with the PANSS total or GAF score (Table 2).

The MTL Glx to Cr ratio was positively associated with the PANSS total score ($F_{1,128.7} = 4.508, \ P = .04, \ n = 132$) (Figure 3). The Glx to Cr ratio increased by 0.06 per 10 points ($SE = 0.03$).
Table 1. Association of Age and Antipsychotic Medication With Glutamatergic Metabolite Levels and Total Creatine Plus Phosphocreatine Levels in Patients and Healthy Volunteers

<table>
<thead>
<tr>
<th>Brain region and source</th>
<th>Por HV, No.</th>
<th>Clinical variable, mean (SD)</th>
<th>Model 1: main effects</th>
<th>Model 2: interaction effects (age × diagnosis or CPZE dose + age)</th>
<th>Model comparison</th>
<th>Residual deviance</th>
<th>P value</th>
<th>Model selected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medial frontal cortex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 Studies 3, 7, 11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P: 705</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HV: 712</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Studies 3, 13, 14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P: 283</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glutamate, Cr-scaled</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25 Studies 3, 7, 11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P: 797</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HV: 737</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 Studies 3, 13, 14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P: 348</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glutamate, CSF-corrected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18 Studies 3, 7, 11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P: 630</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HV: 596</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 Studies 3, 13, 14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P: 276</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Brain region and source</th>
<th>P or HV, No.</th>
<th>Metabolite, estimated mean (SE)</th>
<th>Clinical variable, mean (SD)</th>
<th>Model 1: main effects</th>
<th>Model 2: interaction effects (age + diagnosis or CPZE dose + age)</th>
<th>Model comparison</th>
<th>AIC</th>
<th>Residual deviance</th>
<th>P valueb</th>
<th>Model selected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gtx, Cr-scaled</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 Studies7,11,24,44,46,47,49,50,54,57,59,63-68</td>
<td>P: 705</td>
<td>HV: 652</td>
<td>P: 1.65 (0.07)</td>
<td>Age</td>
<td>P: 30.74 (10.47)</td>
<td>H: 28.71 (9.04)</td>
<td>Age</td>
<td>F1,1345.4 = 15.685, P &lt; .001</td>
<td>Est (SE), −0.0036 (0.0009)</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>12 Studies7,13,14,24,37,38,40,42,44,49,57,65</td>
<td>P: 324</td>
<td>CPZE</td>
<td>1.61 (0.11)</td>
<td>CPZE</td>
<td>400.64 (394.52)</td>
<td></td>
<td>Age</td>
<td>F1,1344.9 = 2.133, P = .14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gtx, CSF-corrected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 Studies7,11,24,42,44,46,47,50,54,57,59,66,68</td>
<td>P: 573</td>
<td>HV: 519</td>
<td>P: 16.85 (1.04)</td>
<td>Age</td>
<td>P: 30.48 (10.57)</td>
<td>H: 28.78 (9.02)</td>
<td>Age</td>
<td>F1,1082.0 = 0.631, P = .43</td>
<td>Diagnosis</td>
<td>F1,1079.2 = 5.287, P = .02</td>
</tr>
<tr>
<td>9 Studies7,13,14,24,38,40,42,44,65</td>
<td>P: 259</td>
<td>CPZE</td>
<td>15.80 (1.45)</td>
<td>CPZE</td>
<td>400.48 (424.59)</td>
<td></td>
<td>Age</td>
<td>F1,1251.1 = 6.326, P = .01</td>
<td>Est (SE), −0.0011 (0.0004)</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
### Table 1. Association of Age and Antipsychotic Medication With Glutamatergic Metabolite Levels and Total Creatine Plus Phosphocreatine Levels in Patients and Healthy Volunteers* (continued)

<table>
<thead>
<tr>
<th>Brain region and source</th>
<th>For HV, No.</th>
<th>Metabolite, estimated mean (SE)</th>
<th>Clinical variable, mean (SD)</th>
<th>Model 1: main effects</th>
<th>Model 2: interaction effects (age × diagnosis or CPZE dose + age)</th>
<th>Model comparison</th>
<th>AIC</th>
<th>Residual deviance</th>
<th>P value</th>
<th>Model selected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medial temporal lobe</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cr</td>
<td>7 Studies</td>
<td>P: 120</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6,40,43</td>
<td>HV: 157</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5,11</td>
<td>P: 5.15 (1.09)</td>
<td>Age</td>
<td>F&lt;sub&gt;1,270.5&lt;/sub&gt; = 1.738, P = .19</td>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HV: 5.13 (1.09)</td>
<td></td>
<td>F&lt;sub&gt;1,270.6&lt;/sub&gt; = 0.033, P = .86</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P: 23.81 (5.75)</td>
<td></td>
<td>Age × diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HV: 24.40 (6.01)</td>
<td></td>
<td>F&lt;sub&gt;1,270.2&lt;/sub&gt; = 0.022, P = .88</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P: 23.81 (5.75)</td>
<td></td>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HV: 24.40 (6.01)</td>
<td></td>
<td>F&lt;sub&gt;1,270.3&lt;/sub&gt; = 0.036, P = .85</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P: 23.81 (5.75)</td>
<td></td>
<td>Age × diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HV: 24.40 (6.01)</td>
<td></td>
<td>F&lt;sub&gt;1,270.2&lt;/sub&gt; = 0.022, P = .88</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glx, Cr-scaled</td>
<td>3 Studies</td>
<td>P: 68</td>
<td></td>
<td>F&lt;sub&gt;1,65.1&lt;/sub&gt; = 1.278, P = .26</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>40,52,53</td>
<td>HV: 157</td>
<td></td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>56,67,70</td>
<td>P: 4.78 (2.83)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52,52,53,56</td>
<td>HV: 4.78 (2.83)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52,52</td>
<td>P: 4.78 (2.83)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52,56,67,70</td>
<td>P: 4.78 (2.83)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>54,56,58,67</td>
<td>P: 4.78 (2.83)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8 Studies</td>
<td>P: 143</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6,40,43</td>
<td>HV: 151</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52,52,56,67</td>
<td>P: 1.90 (0.14)</td>
<td>Age</td>
<td>F&lt;sub&gt;1,293.7&lt;/sub&gt; = 2.650, P = .10</td>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52,52</td>
<td>HV: 1.91 (0.13)</td>
<td></td>
<td>F&lt;sub&gt;1,293.9&lt;/sub&gt; = 0.041, P = .84</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52,52</td>
<td>P: 25.70 (6.93)</td>
<td></td>
<td>Age × diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52,52</td>
<td>HV: 24.20 (5.16)</td>
<td></td>
<td>F&lt;sub&gt;1,293.8&lt;/sub&gt; = 0.049, P = .48</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P: 25.70 (6.93)</td>
<td></td>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HV: 24.20 (5.16)</td>
<td></td>
<td>F&lt;sub&gt;1,293.9&lt;/sub&gt; = 0.041, P = .84</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P: 25.70 (6.93)</td>
<td></td>
<td>Age × diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HV: 24.20 (5.16)</td>
<td></td>
<td>F&lt;sub&gt;1,293.8&lt;/sub&gt; = 0.049, P = .48</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P: 1.90 (0.14)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HV: 1.91 (0.13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P: 1.90 (0.14)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AIC, Akaike information criterion; CPZE, chlorpromazine equivalent dose; Cr, creatine plus phosphocreatine; CSF, cerebrospinal fluid; Est, estimate; Glx, glutamate plus glutamine; HV, healthy volunteers; NA, not applicable; P, patients.

* If age and CPZE dose are significantly associated with glutamatergic metabolites, then model 1 including CPZE is compared with model 2 including both CPZE and age. When χ² test for model comparison is not significant, then the simplest model is selected.

b Determined by use of the χ² test.
Figure 2. Correlations Between Chlorpromazine Equivalent (CPZE) Dose and Medial Frontal Cortex (MFC) Glutamatergic Metabolites

Subsequent analysis found a positive association between the Glx to Cr ratio and the PANSS negative score ($F_{1,129} = 10.162, P = .002, n = 132$), such that the ratio increased by 0.2 per 10 points (SE = 0.07). No significant association was found for the PANSS positive score. The GAF data were unavailable. A higher Glx to Cr ratio was associated with a worse CGI score ($F_{1,269} = 7.583, P = .006, n = 76$), whereby the ratio increased by 0.2 per point on the CGI scale (SE = 0.06).

In the MFC, the PANSS total score was negatively associated with age, such that younger patients had more severe symptoms (eTable 2 in the Supplement). We compared whether the variance in the Glu to Cr ratio was best explained by age, PANSS total score, or both. The model including both age and PANSS total score showed the best fit (Table 2). The PANSS total score and CPZE dose were positively associated in the meta-analysis sample, such that patients with more severe symptoms received a higher CPZE dose (eTable 2 in the Supplement).

Discussion

We conducted a participant-level mega-analysis to assess the association between 1H-MRS glutamatergic metabolite levels and the clinical and demographic features of schizophrenia. The main findings were negative associations of glutamatergic metabolite levels in the MFC with age in both patients with schizophrenia and healthy individuals and with the dose of antipsychotic medication in patients. Higher MFC Glu to Cr ratios were associated with more severe total and positive symptoms and with a lower level of overall functioning. In the MTL, elevated Glx to Cr ratios were associated with more severe total and negative symptoms and with worse CGI scores. In patients, MFC Glu levels were lower than in healthy volunteers irrespective of age, and there was a nonsignificant trend for lower Cr levels in patients. In the MFC, Cr levels, a measure commonly thought to be independent of age, increased with age in both patients and healthy volunteers. Overall, these results indicate that higher Glu levels may be associated with greater illness severity but that Glu levels may be reduced through effective antipsychotic treatment to below those observed in healthy volunteers.

The finding that MFC Glu levels decrease with age in patients with schizophrenia in a manner similar to healthy volunteers suggests that these reductions may reflect normal aging processes in this brain region (2%-3% reduction of mean Glu metabolite per decade). This is consistent with a recent meta-analysis of brain Glu metabolite levels in normal aging, which reports a larger effect size for Glu than Glx for age, as glutamine (part of the Glx signal) increases with age. In contrast to that meta-analysis, our mega-analysis did not detect changes associated with age in the MTL. This inconsistency may be due to the smaller number of studies available in this brain region, limiting our analysis to Glx levels and precluding assessment of Glu levels. One recent metaregression observed an accelerated effect of aging in patients compared with healthy volunteers, however, this association may have been caused by a group of patients at ultra-high risk. Therefore, reduced Glu levels in patients compared with healthy volunteers in previous reports may not have been caused by greater age-related decline.

Conversely, MFC Cr levels increased with age in both patients and healthy volunteers (2% increase of mean Cr level per decade), consistent with previous studies, although I study reports no association. Creatine and phosphocreatine are involved in energy metabolism, and increased levels may re-
flect more burden on this system or increased glial cell numbers and activation with age.77,78 Caution should be taken when using Cr as a reference metabolite in the MFC because there was a trend for lower levels in patients. This lower level may have masked Glu differences between cases and controls, and thus lower patient Glu levels were detected only for CSF-corrected metabolites. Our findings are consistent with a report that the anterior cingulate cortex Cr level is negatively associated with schizophrenia spectrum liability.79 Therefore, future studies should prioritize CSF-corrected measures.

Our finding of lower MFC glutamatergic metabolite levels in patients with schizophrenia relative to healthy volunteers is consistent with a recent meta-analysis.4 Our study indicates that age and antipsychotic medication were independently associated with MFC Glu levels because the model incorporating both of these uncorrelated measures

---

**Figure 3. Correlations Between Medial Frontal Cortex (MFC) and Medial Temporal Lobe (MTL) Glutamatergic Metabolites and Positive and Negative Syndrome Scale (PANSS) Scores**

<table>
<thead>
<tr>
<th>A</th>
<th>Glu/Cr vs PANSS total score</th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
<td>Glu/Cr vs PANSS positive score</td>
</tr>
<tr>
<td>C</td>
<td>Glu/Cr vs PANSS total score</td>
</tr>
<tr>
<td>D</td>
<td>Glu/Cr vs PANSS negative score</td>
</tr>
</tbody>
</table>

---

A. Positive association between the MFC glutamate to total creatinine plus phosphocreatine ratio (Glu/Cr) and the PANSS total score.5,11,24,25,35,40,42-47,51,57,60,65

B. PANSS positive score.40,45,52,53,56

C. Positive association between the MTL glutamate plus glutamine to Cr ratio (Glx/Cr) and PANSS total score.

D. PANSS negative score.40,45,52,55,56

The black line represents the linear mixed model with SE represented by the gray shaded areas; the random-intercept models for each study listed are shown in different colors.
Table 2. Associations of Measures of Symptom Severity and Social and Occupational Functioning With Glutamatergic Metabolites and Total Creatine and Phosphocreatine Levels

<table>
<thead>
<tr>
<th>Brain region and source</th>
<th>Glutamatergic metabolite, estimated mean (SE)</th>
<th>Clinical variable, mean (SD)</th>
<th>Statistics</th>
<th>Estimate (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medial frontal cortex</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cr</td>
<td>14 Studies 5,11,24,35,40,42,47,51,54,65</td>
<td>559 9.21 (0.55) PANSS total: 65.90 (18.36)</td>
<td>$F_{1,548.9} = 0.365, P = .55$</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>6 Studies 5,40,46,51,66</td>
<td>169 9.06 (0.42) GAF: 49.76 (12.50)</td>
<td>$F_{1,164.2} = 2.013, P = .16$</td>
<td>NA</td>
</tr>
<tr>
<td>Glutamate, Cr-scaled</td>
<td>17 Studies 5,11,24,35,40,42-47,51,55,65</td>
<td>668 1.25 (0.07) Model 1: PANSS total: 65.44 (18.90)</td>
<td>$F_{1,659.1} = 5.819, P = .02$</td>
<td>0.001 (0.0005)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$F_{1,661.5} = 14.960, P &lt; .001$</td>
<td>−0.0036 (0.0009)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$F_{1,659.3} = 4.735, P = .03$</td>
<td>0.0011 (0.0005)</td>
</tr>
<tr>
<td></td>
<td>15 Studies 5,11,24,35,40,42-47,51,57,65</td>
<td>625 1.30 (0.06) PANSS positive: 16.15 (6.04) PANSS negative: 16.87 (6.30)</td>
<td>$F_{1,615.7} = 4.382, P = .004$</td>
<td>0.0035 (0.0017)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$F_{1,614.3} = 0.478, P = .49$</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>6 Studies 5,40,46,51,66</td>
<td>178 1.23 (0.09) GAF: 50.04 (12.85)</td>
<td>$F_{1,171.8} = 13.152, P = .001$</td>
<td>−0.0041 (0.0011)</td>
</tr>
<tr>
<td>Glutamate, CSF-corrected</td>
<td>12 Studies 5,11,24,35,40,42-47,65</td>
<td>527 11.90 (0.62) PANSS total: 65.46 (18.49)</td>
<td>$F_{1,520.8} = 2.231, P = .14$</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>5 Studies 5,40,46,65</td>
<td>140 11.55 (0.72) GAF: 50.57 (12.81)</td>
<td>$F_{1,135.1} = 2.043, P = .16$</td>
<td>NA</td>
</tr>
<tr>
<td>Glu, Cr-scaled</td>
<td>15 Studies 5,11,24,35,40,42-44,65</td>
<td>581 1.60 (0.09) PANSS total: 64.97 (18.26)</td>
<td>$F_{1,571.3} = 0.487, P = .48$</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>6 Studies 5,40,46,49,65</td>
<td>155 1.56 (0.17) GAF: 48.93 (14.07)</td>
<td>$F_{1,149.6} = 1.720, P = .19$</td>
<td>NA</td>
</tr>
<tr>
<td>Glu, CSF-corrected</td>
<td>11 Studies 5,11,24,35,40,42-44,47,65</td>
<td>497 15.48 (0.86) PANSS total: 65.99 (18.54)</td>
<td>$F_{1,492.4} = 0.227, P = .63$</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>5 Studies 5,40,46,49,65</td>
<td>131 15.30 (0.87) GAF: 50.53 (13.05)</td>
<td>$F_{1,128.1} = 0.373, P = .54$</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Medial temporal lobe</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cr</td>
<td>4 Studies 40,43,52,53</td>
<td>109 5.03 (2.03) PANSS total: 71.79 (15.46)</td>
<td>$F_{1,104.1} = 0.797, P = .37$</td>
<td>NA</td>
</tr>
<tr>
<td>Glu, Cr-scaled</td>
<td>5 Studies 40,43,52,53,56</td>
<td>132 1.90 (0.19) PANSS total: 73.94 (15.50)</td>
<td>$F_{1,128.7} = 4.508, P = .04$</td>
<td>0.0057 (0.0027)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$F_{1,129.7} = 0.000, P = .98$</td>
<td>−0.0212 (0.0067)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$F_{1,129.9} = 10.162, P = .002$</td>
<td>0.1976 (0.0598)</td>
</tr>
</tbody>
</table>

**Abbreviations:** AIC, Akaike information criterion; CGI, Clinical Global Impression; Cr, creatine plus phosphocreatine; GAF, Global Assessment of Functioning; Glu, glutamate; Glx, glutamate plus glutamine; NA, not applicable; PANSS, Positive and Negative Syndrome Scale.

*Age and PANSS total score are both significantly associated with the medial frontal cortex Glu to Cr ratio, so we compared whether variance in the Glu to Cr ratio was best explained by model 1 including PANSS total score or model 2 including both PANSS total score and age (linear mixed methods estimated with maximum likelihoods). Model 2 showed the best fit (AIC, −98.7; residual deviance, −108.7) compared with model 1 (AIC, −85.9; residual deviance, −93.9) (P < .001, determined by use of the χ² test).
showed the best fit. This result suggests that findings of reduced Glu levels in patients compared with healthy volunteers are not associated with accelerated aging in patients but may be explained by greater antipsychotic exposure, although lower Glu levels have been reported in minimally treated patients with first-episode psychosis. This finding may explain reports of reduced anterior cingulate cortex Glu levels in patients with chronic schizophrenia compared with healthy volunteers. Indeed, a large longitudinal study reports a decrease in Cr-scaled Glu levels with treatment. Antipsychotic medication may reduce Glu levels indirectly, secondary to a reduction in dopaminergic signaling via striatocortical feedback loops. Studies indicate that this result is not necessarily associated with symptom improvement and that Glu levels remain elevated in patients nonresponsive to treatment, despite higher or similar doses of medication.

Our third finding was that higher glutamatergic metabolite levels in both the MFC and MTL were associated with more severe symptoms and lower functioning. In the sample, younger patients were more likely to have severe symptoms, and the model incorporating both age and symptoms provided the best fit for the Glu data. Patients with more severe symptoms received a higher CPZEdose; thus, the association of symptoms with Glu level is not better explained by medication exposure. When symptom dimensions were subsequently examined, Glu metabolite levels in the MFC were associated with positive symptoms, whereas those in the MTL were associated with negative symptoms. The MFC and MTL are key brain regions implicated in schizophrenia. Glutamatergic outputs from these regions regulate dopamine release in the striatum, and excess dopamine release may-underlie the development of psychotic symptoms. Hippocampal Glu level alterations may also be associated with learning and memory, relevant to negative symptoms. Associations with symptoms were observed for Cr-scaled but not CSF-corrected values. This association appears unlikely to be caused by creatine because creatine level was not associated with symptom severity.

Strengths and Limitations
The strengths of the present study include the large patient sample (more than 700 patients), which enabled linear mixed models to account for potential collinearity. Mega-analyses are reported to be more sensitive than meta-analyses owing to narrower confidence intervals. Because data were assembled from different countries, the sample represents varying demographic features and clinical treatments.

The process of combining data from multiple independent sites also has limitations. The IH-MRS acquisition protocols, MR imaging platforms, and scaling methods differed among studies, which we controlled for in the analysis by using linear mixed models to control for site effects and by separately considering CSF-corrected data from Cr-scaled data. Ideally, future prospective multicenter studies would further harmonize IH-MRS acquisition and correction methods to enable more reliable data synthesis. Nevertheless, harmonization will always be constrained by the use of different MR imaging platforms across centers. Despite using established rating scales, there is a possibility of site effects associated with clinical assessment scores and CPZE dose calculations. Owing to a lack of data, we were unable to examine other brain regions that may be associated with schizophrenia pathophysiology. Therefore, we cannot determine whether the observed associations extend to other brain regions. The CPZE dose was not available for all studies; thus, analyses were restricted to smaller samples. Our analysis of the association between medication and Glu levels relied on cross-sectional data. Longitudinal studies can better examine the causal association between these factors, but our results are consistent with longitudinal studies reporting reduced MFC glutamatergic metabolite levels with treatment. Antipsychotic dose was associated with CSF-corrected Glu metabolite levels but not with Cr-scaled values. This finding contrasts with a large longitudinal IH-MRS study finding a reduction in Cr-scaled Glu level with treatment. Finally, mega-analyses rely on contributed data, resulting in data omission.

Conclusions
These findings have important implications for MRS studies in schizophrenia. They highlight the value of matching or adjusting for age, prioritizing CSF-corrected measures over Cr-scaled metabolite levels, and considering antipsychotic dose as an explanatory factor when comparing Glu levels between patients and healthy volunteers. The finding of elevated Glu levels in patients with more severe symptoms provides further support for the use of glutamatergic measures as a potential biomarker of illness severity, alongside other measures, and the development of novel treatments that target brain glutamatergic function.
Affiliations of The 1H-MRS in Schizophrenia

In their study, the investigators from various institutions around the world contributed to the research, highlighting the collaborative nature of scientific research.

Author Contributions:

Dr. Merritt had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interest Disclosures:

Dr. Bortol received an employee at COMPASS Pathways Ltd after the completion of and unrelated to the present work. Dr. Bortol reported receiving royalties from Uptodate outside the submitted work.

Dr. de la Fuente-Sandoval reported receiving personal fees from Janssen (Johnson & Johnson) and receiving grants from Boehringer Ingelheim outside the submitted work.
Dr Gallant reported receiving grants from the German Federal Ministry of Education and Research and from German Science Foundation; and receiving personal fees from Boehringer Ingelheim, Eli Lilly and Company, Janssen-Cilag, Lundbeck, and Otsuka. Dr Goldstein is now referred to by her maiden name, Dr McIlwain. Dr Goto reported receiving personal fees from Meiji Seika, Yoshitomiyakuhin, and Novartis outside the submitted work. Dr Howes reported receiving investigator-initiated research funding or personal fees from Angelini, Autfony, Biogen, Boehringer Ingelheim, Eli Lilly and Company, Heptares, Global Medical Education, Invivo, Janssen, Lundbeck, Mylan, Neurocrine, Otsuka, Sunovion, Rand, Research Triangle Institute, and having a patent for the use of dopaminergic imaging. Dr Jaurhar reported receiving personal fees from Sunovian and nonfinancial support from Lundbeck outside the submitted work. Dr Kato reported receiving grants from Eisai, Mitsubishi Tanabe Pharma Corporation, Otsuka, Sumitomo Dainippon Pharma, Shionogi, and Co, and Takeda Pharmaceutical, and receiving personal fees from Astellas Pharma Inc, Eisai, Eli Lilly Japan, GlaxoSmithKline, Kaneka Foundation for the Promotion of Medical Science, Kyowa Hakko Kirin, Kyowa Hakko Kirin, Japan Clinical Industry, Janssen Asia Pacific, Janssen Pharmaceutical, Meiji Seika Pharma, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical, Nippon Boehringer Ingelheim, Otsuka Pharmaceutical, Pfizer Japan, Shionogi & Co, Sumitomo Dainippon Pharma, Taisho Pharmaceutical, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, and Yoshitomiyakuhin outside the submitted work. Dr Kegeles reported receiving grants from the National Alliance for Research on Schizophrenia and Depression during the conduct of the study. Dr Lauriello reported being on the advisory panel for Alkermes and on the data management safety board for Bioexcel Therapeutic. Dr Liemburg reported receiving grants from AstraZeneca, European Research Council, European Young Investigator Awards, and Stichting Roos during the conduct of the study. Dr McGuire reported receiving personal fees from Sunovian and Takeda. Dr McIlwain reported receiving grants from the New Zealand Schizophrenia Research Group and a fellowship from the New Zealand Federation of Graduate Women during the conduct of the study; and becoming employed at Synaes Health after the collection and analysis of data for the present work but has not worked on any projects there related to schizophrenia or psychiatry. Dr Palaniyapann reported receiving personal fees from the Canadian Psychiatric Association, Janssen Canada, Otsuka Canada, and Otsuka Pharmaceutical UK outside the submitted work; receiving grants from Janssen Canada, Otsuka Canada, and Sunovion outside the submitted work; and receiving royalties from Oxford University Press. Dr Pantelis reported receiving grants from the Australian National Health & Medical Research Council during the conduct of the study; grants from Lundbeck Foundation; and personal fees from Lundbeck Australia Pty Ltd outside the submitted work. Dr Purdon reported receiving grants from the Canadian Institute of Health Research during the conduct of the study; and personal fees from Lundbeck Canada outside the submitted work. Dr Schaefer reported receiving grants from The Stanley Medical Research Institute during the conduct of the study; and receiving personal fees from Janssen-Cilag, Gilead Sciences GmbH, Hexas-AG, and Servier outside the submitted work. Dr Shungu reported receiving personal fees from Icahn School of Medicine at Mount Sinai and the US National Institutes of Health outside the submitted work. Dr Stone reported being a principal investigator or subinvestigator on studies sponsored by Teakeda, Janssen, and Lundbeck; and attending investigator meetings at Allergan outside the submitted work. Dr Taylor reported receiving grants from the Ontario Mental Health Foundation and the Canadian Institute of Health Research during the conduct of the study. Dr Thébèrge reported receiving grants from the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council, and the Canada Foundation for Innovation during the conduct of the study; and receiving personal fees from Siemens Healthineers Canada. Dr Tibbo reported receiving grants from the Alberta Health Foundation for Medical Research and the Canadian Institutes for Medical Research during the conduct of the study; and personal fees from Janssen, Lundbeck, and Otsuka outside the submitted work. Dr Xin reported receiving grants from the Swiss National Science Foundation and Société des Produits Nestlé outside the submitted work. Dr Yamase reported receiving personal fees from Eli Lilly and Company, Janssen, Meiji Seika Pharma, Merck Sharp & Dohme, Mochida, Otsuka, Pfizer, Sumitomo Dainippon, Takeda, and Yoshitomiyakuhin; and receiving a research grant from Eisai. No other disclosures were reported.

Funding/Support: This study was supported by a PhD studentship from UK Medical Research Council and grant MR/S003436/1 from the Medical Research Council to Dr Merritt; grant MR/L003988/1 from the Medical Research Council to Dr Eagerton; and grant HEALTH-F2-2010-242114 from the European Commission within the 7th Framework Programme. This study presents independent research funded in part by the National Institute for Health Research Biomedical Research Centre at South London and Maudsley National Health Service Foundation Trust and King’s College London. Dr Camilo de la Fuente-Sandoval was awarded research grants 119280, 182279, and 261995 from the Sao Paulo Research Foundation – FAPESP 5A outside the submitted work. Dr Yamasu reported receiving personal fees from Eli Lilly and Company, Janssen, Meiji Seika Pharma, Merck Sharp & Dohme, Mochida, Otsuka, Pfizer, Sumitomo Dainippon, Takeda, and Yoshitomiyakuhin; and receiving a research grant from Eisai. No other disclosures were reported.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Glutamatedysfunctioninpeoplewithprodromal
episodepsychosis:relationshiptograymatter
resonancespectroscopystudies.

medicatedschizophrenicpatients:aproton
magneticresonancespectroscopy.

cortexofnever-treated
archpsych.

onprefrontalcorticalconnectivitybettermodel
earlythanchronicschizophrenia.

5. Stone JM, Day F, Tagasari H, et al. OASIS.
Glutamateandglutamineinpeoplewithprodominal
symptoms:relationshiptogroupmattered
volume.

Glutamateandglutamineinpeoplewithprodominal
symptoms:relationshiptogroupmattered
volume.

at4tesinallytreatedearlyschizophrenia.

prefrontalcortexofnontreated
schizophrenicpatientsandhealthycontrols
byprotonmagneticspectroscopy.

intheprefrontalcortexinchronicbutnotin
earlyepisodeswithschizophrenia:apronoton
magneticspectroscopy.

neuroleptic-naiveandchronic
medicatedschizophrenicpatients:aiproton
magneticspectroscopy.

frontalglutamate+glutamine
andN-acetylaspartateinpatientswithchronic
schizophreniabutnotinthoseatclinicalhighrisk
forpsychosisorwithfirst-episode
schizophrenia.

MRsin_twinsdisordertoschizophrenia.

REFERENCES

Working Group of the Psychiatric Genomics
Consortium. Biological insights from 108
schizophrenia-associatedgeneticloci.

McGuire PK. Natureofglutamatealterations
in schizophrenia:ameta-analysisofproton
magneticresonanceimagingstudies.

3. Anticevic A, Corlett PR, Cole MW, et al. N-methyl-D-aspartate receptor antagonist effects
onprefrontalcorticalconnectivitybettermodel
earlythanchronicschizophrenia.

4. Sydoren VJ, Roalf DR. A meta-analysis
of ultra-high field glutamate, glutamine, GABA
and glutathione 1H-MRS in psychosis.

to initialantischizophrenic treatment in
firstepisodepsychosisisrelatedtoanteriorcingulate
glutamatelevels:amulticentre'1H-MRS study.

Glutamateandglutamineinpeoplewithprodominal
symptoms:relationshiptogroupmattered
volume.

at4tesinallytreatedearlyschizophrenia.

medialprefrontalcortexofnontreated
schizophrenicpatientsandhealthycontrols
byprotonmagneticspectroscopy.

intheprefrontalcortexinchronicbutnotin
first-episodepatientswithschizophrenia:apronoton
magneticspectroscopy.

neuroleptic-naiveandchronic
medicatedschizophrenicpatients:aiproton
magneticspectroscopy.

frontalglutamate+glutamine
andN-acetylaspartateinpatientswithchronic
schizophreniabutnotinthoseatclinicalhighrisk
forpsychosisorwithfirst-episode
schizophrenia.

MRsin_twinsdisordertoschizophrenia.

in schizophrenia using 3-Tesla proton magnetic
resonance spectroscopy (1H-MRS).

cingulate and thalamus of medicated patients with chronic
schizophrenia and healthy comparison subjects
measured with 4.0-T proton MRI.

15. Palaniyappan L. Progressivecortical
reorganisation:aframeworkforinvestigating
structuralchangesinschizophrenia.

levels in schizophrenia: a 1H-MRS and pCASL study.

and neuronal dysfunction in gray and white matter:
a spectroscopic imaging study in a large
schizophrenia sample.

in first-episode schizophrenia.

matter and social functioning correlates of
 glutamatergic metabolism loss in schizophrenia.

intheprefrontalcortexinchronicbutnotin
first-episodepatientswithschizophrenia:apronoton
magneticspectroscopy.

neuroleptic-naiveandchronic
medicatedschizophrenicpatients:aiproton
magneticspectroscopy.

frontalglutamate+glutamine
andN-acetylaspartateinpatientswithchronic
schizophreniabutnotinthoseatclinicalhighrisk
forpsychosisorwithfirst-episode
schizophrenia.

MRsin_twinsdisordertoschizophrenia.

in schizophrenia using 3-Tesla proton magnetic
resonance spectroscopy (1H-MRS).

cingulate and thalamus of medicated patients with chronic
schizophrenia and healthy comparison subjects
measured with 4.0-T proton MRI.

15. Palaniyappan L. Progressivecortical
reorganisation:aframeworkforinvestigating
structuralchangesinschizophrenia.

levels in schizophrenia: a 1H-MRS and pCASL study.
Association of Age, Antipsychotic Medication, and Symptoms With Brain Glutamate Level in Schizophrenia

Original Investigation Research

JAMA Psychiatry
jamapsychiatry.com

Association of Age, Antipsychotic Medication, and Symptoms With Brain Glutamate Level in Schizophrenia: a systematic review of longitudinal 1H-MRS studies.

34

1093/ijnp/pyx076

Neuropsychopharmacology
2011;36(9):1781-1791. doi:10.1038/npp.2011.65

35


36


37


38


39


40


41


42


43


44


45


46


47


48


49


50


51


52


53


54

Wood SJ, Yücel M, Wellard RM, et al. Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. Schizophr Res. 2007;94(1-3):328-331. doi:10.1016/j.schres.2007.05.008

55


56


57


58


